阿达木单抗联合甲氨蝶呤优化银屑病治疗(OPTIMAP):一项实用性、单盲、研究者发起的随机对照试验研究方案
OPTIMAP为研究者发起的多中心随机对照试验,比较阿达木单抗联合甲氨蝶呤与阿达木单抗单药治疗银屑病,主要结局为第49周阿达木单抗药物生存率,计划样本量93例,2014年3月开始招募。
要点
- 比较阿达木单抗联合甲氨蝶呤与阿达木单抗单药治疗银屑病。
- 主要结局为第49周阿达木单抗药物生存率。
- 计划样本量93例,截至报告时已随机36例。
核心结论
- OPTIMAP是首个在银屑病人群中考察阿达木单抗联合甲氨蝶呤的随机对照试验。
- 作者期望该研究提供长期治疗结局的临床数据,并通过药代动力学和单核苷酸多态性分析支持该靶向治疗更个体化的方法。
研究设计与样本
- 研究者发起的多中心随机对照试验,比较阿达木单抗联合甲氨蝶呤与阿达木单抗单药治疗银屑病患者。
- 主要结局为第49周阿达木单抗药物生存率;其他结局包括疾病严重程度和生活质量改善、耐受性和安全性。
- 将检测抗阿达木单抗抗体和阿达木单抗血清浓度,并评估基因型与临床结局之间的相关性。
- 2014年3月开始患者招募;截至报告时已随机36例,计划样本量93例。
主要发现
- 截至报告时已随机36例,计划样本量93例以达到足够的样本量。
- 许多更多患者已被(预)筛选。
- 作者经验中,招募的主要限制是既往阿达木单抗治疗史以及既往对甲氨蝶呤的不耐受或毒性。
局限性
- 作者经验中,招募的主要限制是既往阿达木单抗治疗史以及既往对甲氨蝶呤的不耐受或毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The introduction of anti-tumor necrosis factor medications has revolutionized the treatment of psoriasis with achievement of treatment goals (Psoriasis Area and Severity Index score 75, remission) that are not usually met with conventional systemics. Nevertheless, some patients continue to experience persistent disease activity or treatment failure over time. Strategies to optimize treatment outcomes include the use of concomitant methotrexate, which has demonstrated beneficial effects on pharmacokinetics and treatment efficacy in psoriasis and other inflammatory diseases. METHODS: This is an investigator-initiated, multicenter randomized controlled trial (RCT) designed to compare the combination treatment of adalimumab and methotrexate with adalimumab monotherapy in patients with psoriasis. The primary outcome is adalimumab drug survival at week 49. Other outcomes include improvement in disease severity and quality of life, tolerability, and safety. Moreover, anti-adalimumab antibodies and adalimumab serum concentrations will be measured and correlations between genotypes and clinical outcomes will be assessed. Patient recruitment started in March 2014. Up to now, 36 patients have been randomized. Many more patients have been (pre)screened. A total of 93 patients is desired to meet an adequate sample size. In our experience, the main limitation for recruitment is prior adalimumab therapy and intolerability or toxicity for methotrexate in the past. DISCUSSION: OPTIMAP is the first RCT to examine combination therapy with adalimumab and methotrexate in a psoriasis population. With data derived from this study we expect to provide valuable clinical data on long-term treatment outcomes. These data will be supported by assessment of the impact of concomitant methotrexate on adalimumab pharmacokinetics. Furthermore, the influence of several single nucleotide polymorphisms on adalimumab response will be analyzed in order to support the development of a more personalized approach for this targeted therapy. TRIAL REGISTRATION: NTR4499 . Registered on 7 April 2014.
引用
- Busard CI, Menting SP, van Bezooijen JS, et al. Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial. Trials. 2017. PMID: 28148280. doi:10.1186/s13063-017-1777-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。